Drug Trial Radar · NCT04866017
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
63
Actual
Start
Jun 17, 2021
Primary completion
Oct 17, 2023
Study completion Oct 17, 2023
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Apr 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the safety and efficacy of ociperlimab in combination with tislelizumab compared to durvalumab in adults with stage III unresectable PD-L1-selected non-small cell lung cancer whose disease has not progressed after cCRT.
Conditions
- Non Small Cell Lung Cancer
Interventions
TislelizumabDrug
200 mg intravenously every three weeks
DurvalumabDrug
10 milligrams per kilogram (mg/kg) intravenously once every 2 weeks (or 1500 mg intravenously once every 4 weeks where the dosage has been approved by a local health authority)
OciperlimabDrug
900 milligrams (mg) intravenously every three weeks
ChemotherapyDrug
The chemotherapy regimen for the study treatment was selected at the investigator's discretion and may include one of the following options: * Cisplatin (50 mg/m²) on days 1 to 5 of each cycle, combined with etoposide (50 mg/m²) on days 1 and 8, both administered intravenously for 2 cycles. Each cycle was 28 days. * Carboplatin (AUC 2) weekly for 6 weeks, combined with paclitaxel (40-50 mg/m²) weekly for 6 weeks, both administered intravenously. * Cisplatin (75 mg/m²) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days. * Carboplatin (AUC 5) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days. The pemetrexed plus platinum regimen was only for participants with non-squamous histology.
RadiotherapyRadiation
All participants recieved radiotherapy using either a standardized 3-dimensional conformal radiotherapy technique, or intensity modulated radiotherapy (IMRT) on a linear accelerator delivering a beam energy of ≥ 6 MV. The total dose of radiotherapy was 60 Gy, administered in 30 once-daily fractions of 2 Gy and 5 fractions per week for 6 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)Time frame: From randomization through to the end of study, planned duration was 20 months
Locations
35 sites in 5 countries. Site status is shown where the registry gives one.
XCancer/Centeral Care Center
Bolivar, Missouri
Gold Coast University Hospital
Gold Coast, Australia
Hollywood Private Hospital
Perth, Australia
Southern Medical Day Care Centre
Wollongong, New South Wales, Australia
Townsville Hospital
Douglas, Queensland, Australia
Lyell McEwin Hospital
Elizabeth Vale, South Australia, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Cabrini Hospital
Malvern, Victoria, Australia
Peking University Third Hospital
Beijing, China
Changzhou Cancer Hospital
Changzhou, China
Jieyang People'S Hospital (Jieyang Affiliated Hospital, Sun Yat-Sen University )
Jieyang, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Hunan Cancer Hospital - GCP Office
Changsha, Hunan, China
Nanjing First Hospital
Nanjing, Jiangsu, China
The First Affiliated Hospital of Soochow University Branch Shizi
Suzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, China
Jilin Cancer Hospital
Changchun, Jilin, China
The First Hospital of Jilin University
Changchun, Jilin, China
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
Shandong Cancer Hospital and Institute, Shandong First Medical University
Jinan, Shandong, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
Hangzhou, Zhejiang, China
Instituto Oncologico Dr. Rosell
Barcelona, Spain
Ico Girona
Girona, Spain
Hospital Universitario Fundación Jiménez Díaz
Alcorcón, Madrid, Spain
Changhua Christian Hospital
Changhua, Taiwan
Chung Shan Medical University Hospital
Taichung, Taiwan
Taichung Veterans General Hospital
Taichung, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.